Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
Provided By GlobeNewswire
Last update: Aug 18, 2025
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures
RNA sequencing and circulating tumor cell reduction consistent with tumor cell death
Read more at globenewswire.comNASDAQ:PSTV (10/30/2025, 11:30:01 AM)
0.5479
+0.01 (+1.18%)
Find more stocks in the Stock Screener
